相关实验视频
Updated: May 20, 2025

06:08
Transcranial Pulse Stimulation for Alzheimer's Patients
Published on: April 4, 2025
310
针对神经振荡来提高阿尔茨海默氏症患者的认知能力
Federica Palacino1, Paolo Manganotti1, Alberto Benussi1
1Neurology Unit, Department of Medical, Surgical and Health Sciences, University of Trieste, 34149 Trieste, Italy.
Medicina (Kaunas, Lithuania)
|March 27, 2025
概括
准神经振荡为阿尔茨海默病 (AD) 提供了一个有前途的治疗策略. 神经调节技术在恢复大脑节律,改善记忆力和减少AD病理方面显示出潜力.
科学领域:
- 神经科学是一个神经科学.
- 神经学 神经学
- 生物医学工程 生物医学工程
背景情况:
- 阿尔茨海默病 (AD) 是一种进展性痴呆症,其特点是认知能力下降和特征病理,如粉样蛋白斑块和团.
- 失调的神经振荡与AD的网络功能障碍和记忆障碍有关.
- 针对神经振荡,为阿尔茨海默病提供了一个新的治疗途径.
研究的目的:
- 审查调节神经振荡在阿尔茨海默病的治疗潜力.
- 探索各种神经调节技术及其在临床前和临床环境中的有效性.
- 讨论在AD中基于振荡的疗法所面临的挑战和未来的方向.
主要方法:
- 在动物模型中对感官刺激和跨交替电流刺激 (tACS) 的临床前研究的审查.
- 对重复性横磁刺激 (rTMS) 和深度大脑刺激 (DBS) 的临床试验数据的分析.
- 检查新兴技术,如跨脉动刺激 (TPS) 和自适应神经调节.
主要成果:
- 临床前研究表明,频率调制可以恢复振荡平衡,增强突触可塑性,并减少AD病理.
- 临床试验显示,使用rTMS和DBS可以改善认知能力,特别是在针对记忆网络时.
- 在阿尔茨海默病患者中,马-tACS与增加的胆固醇活性和改善的网络连接相关.
结论:
- 针对神经振荡的神经调节显示出对治疗阿尔茨海默病的重大前景.
- 优化刺激参数,个性化治疗和理解长期影响是关键的挑战.
- 将神经调节与其他疗法结合起来,可能会增强AD患者的认知效益.
相关概念视频
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
86
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
86
Alzheimer's Disease: Treatment
137
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
137
Alzheimer's Disease: Overview
399
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
399

